Introduction
have cyclin D overexpression [1] . p16 INK4A inhibits the catalytic activity of cyclin D-CDK4/6 complex, and increases hypophosphorylated Rb protein, which result in G1 phase cell cycle arrest by inactive Rb-E2F complex [2] [3] . Thus, p16
INK4A functions as an important tumor suppressor as it controls cell cycle progression. The expression level of p16 INK4A is low in primary human fibroblasts and high in senescent fibroblasts [4] [5] . siRNA-mediated p16 INK4A knockdown rescues senescent cells from growth arrest [6] [7] , arguing a critical role of p16
INK4A in replicative senescence. In senescent cells, p53 is also accumulated and activated by acetylation and phosphorylation [8] [9] . In response to oncogenic stimuli, such as ectopic activation of Ras-MAPK pathway, primary fibroblasts exit to premature senescence associated with elevation of p16 INK4A and p53 levels [10] [11] [12] [13] [14] [15] .
E2FBP1/DRIL1/hARID3A is a member of A/T-rich interaction domain (ARID) family protein [16] and an E2F1 associated factor that increases E2F/DP-dependent transcription [17] , a human orthologue of mouse B-cell regulator of IgH transcription (Bright) and drosophila dead ringer (Dri) [18] [19] expressed ubiquitously in various tissues. More recently, we reported that E2FBP1 acts as a transcriptional suppressor against viral immediate early gene transcription in an intrinsic cellular defense uniquely observed in passage-limited human diploid fibroblast (HDF) cells infected with herpes simplex virus type 1 infection [20] . E2FBP1 also functions as a negative regulator of promyelocytic leukemia proteinnuclear bodies (PML-NBs) [21] , which are recognized as gatekeepers of cellular integrity. PML-NBs respond to various cellular events, including the induction of oncogenic transformation and virus infections. The increase in size and numbers of PML-NBs deprive proliferative potential and force cells into premature senescence [22] [23] or apoptosis [24] . During the oncogenic Ras-induced premature senescence, PML is up-regulated through the activation of MAPK cascade and contributes ultimately to the cell cycle arrest and senescence mediated by p16
INK4a
/Rb-and/or p53-pathways [13] [14] [15] . E2FBP1 interacts with the components of PML-NBs such as PML, speckled protein (Sp100), and p53, as well as E2F2/4 in vivo and in vitro. Moreover, siRNA-mediated E2FBP1 knockdown results in increases of PML-NBs in size and number, and subsequently induces PML-dependent premature senescence of HDF cells along with the up-regulation of p16 INK4A and p53 [21] . In agreement with this, the ectopic expression of E2FBP1 rescues oncogenic Ras-induced premature senescence [25] , and thus E2FBP1 plays an essential role for maintenance of proliferative potential of human cells. However, the mechanism by which E2FBP1 dissociates PML-NBs remains elusive.
Here we report that the molecular mechanism of E2FBP1-induced PML-NBs dissociation is through ubiquitin-dependent degradation of PML. Down-regulation of E2FBP1, induced by oncogenic Ras expression, induces premature senescence and requires an intact p16 INK4A -pathway. Therefore, our study reveals that E2FBP1 antagonizes PML-dependent p16
INK4A
/Rb-mediated growth suppression and senescence.
Materials and method

Plasmids and synthetic oligonucleotides
HA-E2FBP1 and HA-PML-IV were subcloned into pcDNA3 to construct expression plasmids. Human H-ras V12 was cloned in pLenti6 for preparation of recombinant lentiviruses. Coding units for shRNAs in double strands were synthesized and linked to U6 promoter in pLenti6 plasmid according to the manufacturer's instructions (Invitrogen, Carlsbad, USA). Sequences for anti-E2FBP1 shRNA are following; A1: CACCGATGT-AACGTGCGCTTCAAGTGTGCTGTCCTTGGAGTG CACGTTGCATC; A2: CACCGAGATTAACGGTATC-GTGTGTGTGCTGTCCACATGATGCCGTTGATCTC; A3: CACCCTGTGGACCCGATACGTGAACGTGTGC-TGTCCGTTCATGTATTGGGTCCGCAG. Anti-p16
INK4A
shRNA was prepared as stated by the researchers [26] , and the sequence of control shRNA was previously described [27] . shRNA expression plasmid, piGENE-E2FBP1 was generated by inserting anti-E2FBP1 shRNA sequence; CAAGCAGTTCTACGGACTCGATGGGGA-CCCCCTTCCTGTCAGGGGTCCCCGTCGAGTTCGT AGAGCTGCTTGGTAC to piGENEtRNA vector (iGENE Therapeutics, Tokyo, Japan) between SacⅠ and KpnⅠ sites.
Cell culture, transfection and infection
TIG-3 human fetal lung derived passage-limited diploid fibroblast cells between populator doubling (PD) number 36 and 50, human cancer cell lines such as KB, A431, Saos2, MCF7, and 293FT human embryonic kidney cell line (Invitrogen, Carlsbad, USA) were cultivated in Dulbecco's modified Eagles medium (DME) supplemented with 8% fetal calf serum (FCS). HCT116 was cultivated in McCoy's 5A medium supplemented with 10% FCS. For transfection with plasmid DNA, cells were plated to be 50% confluent, and transformed with FuGene 6 transfection reagent (Roche Applied Science, Indianapolis, USA). For recombinant lentivirus infection, TIG-3 cells plated between 1×10 6 -2×10 6 cells in a 10 cm dish were incubated with 10 mL of freshly prepared virus stock supernatant that contains 0.5×10 6 -5×10 6 viruses· mL -1 for 12 h in the presence of 6 µg· mL -1 polybrene. The cells were then overlaid with 10 mL of fresh medium containing 4 µg· mL -1 Brasticidin-S-HCl for 30 h and cultivated for 2 d with fresh medium without the Brasticidin. The cells were subsequently replated at 40%-50% confluence and grown until they were analyzed. For growth assay using lentiviruses, TIG-3 cells at 47 PD were infected with lentiviruses carrying expression unit of indicated shRNAs at total multiplicity of infection (MOI)=2 (e.g. MOI=1 of anti-p16
INK4A shRNA-expression virus plus MOI=1 of A2-expression virus: the sum of the virus mixture contains MOI=2). Infected cells were selected with antibiotics, and counted at the indicated cultivation periods.
Lysate preparation and Western blotting
Cells were washed twice with PBS, lysed in the lysis buffer (400 mmol· L -1 NaCl, 50 mmol· L -1 HEPES-Na, pH 7.0, 1 mmol· L -1 ethylene diamine tetraacetic acid (EDTA), and 0.1% NP-40), and clarified by centrifugation. Protein concentration was determined using the BCA protein assay kit (Sigma-Aldrich, St. Louis, USA). The protein sample (30 µg) was separated on SDS-PAGE gels, and transferred to immobion-P membranes (Millipore, Billerica, USA). To detect the antigen, blots were blocked in TBS-T (25 mmol· L -1 tris-HCl, pH 8.0, 137 mmol· L -1 NaCl, and 2.7 mmol· L -1 KCl, and 0.1% Tween 20) containing 5% skim milk (Difco, Detroit, USA) for 30 min, and incubated with primary antibody for 2 h. The blots were incubated with secondary antibody conjugated with horseradish peroxidase for 1 h. Protein bands were visualized by Lumi-Light PLUS western blotting substrate (Roche Applied Science, Indianapolis, USA). Immunoassays were performed with anti-E2FBP1 polyclonal antibody (BL665, Bethyl Laboratories, Montgomery, USA), Anti-p16
INK4A polyclonal (C-20), anti-p21 CIP1 polyclonal, anti-p53 monoclonal (DO-1), anti-PML monoclonal (PG-M3), anti-Cyclin E polyclonal (M-20) and anti-Daxx polyclonal (C-20) antibodies were obtained from Santa Cruz Bio-technology (Santa Cruz, USA). Anti-Sp100 polyclonal was obtained from ChemiconMillipore (Watford, UK). Anti-Ras monoclonal (#18), anti-Rb monoclonal (G3-245), anti-ERK1 monoclonal (MK12), anti-phospho-ERK1/2 (pT202/pY204) monoclonal (#20A), anti-p38/SAPK2a monoclonal (#27), and anti-phospho-p38SAPK (pT180/pY182) monoclonal (#30) antibodies were obtained from BD Biosciences (San Jose, USA). Anti-tubulin monoclonal (DM-1A) was obtained from ICN Biomedicals (Irvine, USA).
Detection of PML ubiquitylation
For ubiquitination assays, 2 d after transfection, cells were treated with 10 µmol· L -1 proteasome inhibitor MG115 for 8 h and harvested by boiling for 5 min in lysis buffer (1% sodium dodecyl sulfate (SDS), 1 mmol· L -1 EDTA in plosphate buffer saline (PBS) for protein analyses.
siRNA-mediated down-regulation
The target sequences for siRNA-Control and E2FBP1 have been described previously [21] . siRNAs were synthesized by Japan Bioservice Co. (Saitama, Japan). Transfection into TIG-3 cells was performed with oligofectamine (Life Technologies, Carlsbad, USA).
SA-β-gal assay
SA-β-gal assay was performed as described [28] . Briefly, cells were fixed with 3% formaldehyde for 5 min, washed with PBS, and incubated at 37 ℃ with staining buffer (1 mg· L -1 5-bromo-4-chloro-3-indolyl-β- 
Colony formation assay
Cancer cell lines were plated at 1×10 6 per 35-mm dish in triplicate and transfected with piGENE vector or piGENE-E2FBP1. Cells were replanted in 100-mm dishes the next day, cultivated in the presence of 5 µg· mL -1 of puromycin for 48 h, and subsequently developed colonies for two weeks in the presence of 1 µg· mL -1 of puromycin. The puromycin-resistant colonies were stained with 0.1% crystal violet and then calculated using ImageJ software.
Results
E2FBP1 induces degradation of PML through polyubiquitylation
To determine whether E2FBP1-dependent dissociation of PML-NBs is a consequence of degradation of PML, 293FT cells were transfected with expression plasmids for HA-E2FBP1, HA-tagged 633-residue isoform IV of PML (HA-PML-IV) which is a major component of PMLNBs, and humanized green fluorescent protein (hrGFP). To eliminate the influence of squelching of transcription factors, the amount of plasmids were adjusted with the empty vector pcDNA3 that contains a cytomegalovirus (CMV) early gene promoter for common to all expression plasmids. Ectopic expression of E2FBP1 reduced the amount of PML-IV in dose-dependent manner whereas no effect was observed in cells expressing hrGFP ( Figure 1A ). E2FBP1 also down-regulated another PML-NB-associated 560-residue isoform VI of PML (HA-PML-VI) ( Figure 1B ). Contrary to these results, siRNA-mediated E2FBP1 depletion [21] resulted in an up-regulation of PML ( Figure 1C) , and the complementation with exogenous E2FBP1 that overcome siRNAmediated down-regulation of E2FBP1 resulted in a distinct down-regulation of exogenous PML-IV ( Figure  1D ). These results confirmed that E2FBP1 down-regulated the expression of PML regardless of its promoter, and thus possibly at the posttranscriptional level, in dose-dependent manner.
To examine whether E2FBP1 mediates polyubiquitylation of PML-IV, 293FT cells were transfected with plasmids expressing HA-PML-IV and E2FBP1. Fortyeight hours of post transfection, cells were further incubated with a proteasome inhibitor MG115 for 8 h prior to harvest. HA-PML-IV was immunoprecipitated with anti-HA antibody, and the immune complexes were subjected to immunoblotting. As shown in Figure 2A , an increase of slower migrating PML populations (≥100 kDa) that was coupled with high molecular weight polyubiquitylated protein species were evident. Moreover, E2FBP1-induced high molecular weight species of HA-PML were modified with Myc-tagged ubiquitin moiety ( Figure 2B ). These results revealed that E2FBP1 induces polyubiquitylation of HA-PML-IV in vivo. ) plated in 6-cm dishes were transformed with 3 µg of expression plasmids mixtures composed of pcDNA3 (vector), pIRES-hrGFP-2, pcDNA-HA-E2FBP1 and pcDNA-HA-PML-IV at indicated ratio. Cell lysates were prepared after two days of cultivation. Thirty-three µg of each lysate was then subjected to immunoblot analyses with antibody for PML (PG-M3), E2FBP1 (BL665) and hrGFP. Open arrowheads and closed arrowheads show endogenous and exogenous antigens, respectively. (B) Both major PML components of PMLNBs are down-regulated under the ectopic expression of E2FBP1. Expression plasmids for either of major PML component of PML-NBs, pcDNA3-HA-PML-IV or pcDNA3-HA-PML-VI was transfected to 293FT cells with or without pcDNA3-HA-E2FBP1, and the cell lysates were similarly subjected to immunoblot analyses. (C) siRNA-mediated down-regulation of endogenous E2FBP1 stabilizes endogenous PML in TIG-3 cells. TIG-3 cells were transformed with siRNA against either E2FBP1 or nonsense control. Two days later, cell lysates were collected, and 15 µg of the lysate protein was subjected to immunoblot analysis for PML, E2FBP1 and actin. (D) siRNA-mediated down-regulation of endogenous E2FBP1 stabilizes exogenous HA-PML-IV, and this stabilization is canceled by simultaneous expression of exogenous E2FBP1. 293FT cells were transfected with siRNA against either E2FBP1 or nonsense control. Two days later, the cells were simultaneously transfected with indicated mixtures containing same siRNA and either of following expression plasmid mixtures; HA-PML-IV plus empty vector (1∶1) or HA-PML-IV plus non-tagged E2FBP1 (1∶1), and cultivated for in a further two days. Fifteen µg of cell lysate proteins were subjected to immunoblotting for HA and E2FBP1. Asterisk indicates a cross -reactive protein and serves as a loading control. 
E2FBP1 down-regulation induces premature senescence
Since siRNA-mediated E2FBP1 knockdown induced PML-dependent premature senescence in human primary fibroblast TIG-3 cells, we tested whether down-regulation of E2FBP1 activates Ras-MAPK pathway that results in up-regulation of PML and oncogene-induced premature senescence. TIG-3 cells infected with either lentivirus expressing efficient anti-E2FBP1 short hairpin RNA (shRNA) A2 or A3 exhibited flat enlarged morphology, a characteristic phenotype of senescence and the expression of SA-ß-gal ( Figure 3A) . SA-ß-gal positive cells were 2.9%±0.15%, 94%±8.5%, and 96%±1.8% for A1, A2, and A3, respectively. As expected, the PML expression level was increased in both A2 and A3-infected cells, but not A1-infected cells ( Figure 3B ). The expression levels of Sp100 and Daxx that are major components of PMLNBs were also increased significantly ( Figure 3B ). Moreover, up-regulation of p16 INK4A and both phosphorylated ERK1/2 (p-ERK1/2) and p38/SAPK (p-p38), and down-regulation of phosphorylated RB were evident in A2 and A3-infected cells but not in A1-infected cells ( Figure 3B ).
Next we tested the effect of oncogenic Ras
V12
, a premature senescence inducer, on the E2FBP1 expression.
Ras
V12 induced the down-regulation of E2FBP1 along with up-regulations of PML, p16 INK4A , and hypophosphorylation of Rb ( Figure 3C ). These results suggest that the Ras-ERK-p38 signaling axis induces PML-dependent premature senescence at least partly through the downregulation of E2FBP1.
p16
INK4A plays a critical role in growth suppression initiated by E2FBP1 down-regulation
To investigate the role of p16 INK4A -Rb pathway on the growth arrest induced by down-regulation of E2FBP1, we depleted p16
INK4A simultaneously with E2F2BP1. Depletion of E2FBP1 showed both growth arrest and the characteristic morphology of senescence [21] (Figure 4A , shControl vs shE2FBP1-A2); however, cells transfected with both shp16
INK4A and shE2FBP1 showed recovery in the growth rate and acquired normal morphology after 10 days of lag phase ( Figure 4A, shp16 INK4A + shE2FBP1-A2). The depletion of both p53 and E2FBP1 increased cell numbers more than four-times greater than that of cells depleted only E2FBP1; however, these double-depleted cells were eventually arrested around Day 15 ( Figure 4B ). These results suggest that p16 INK4A has a critical role in the growth arrest induced by the down-regulation of E2FBP1, whereas p53 has only a minor role.
E2FBP1 depletion suppresses tumor cell growth in the presence of intact p16 INK4A and Rb To further confirm the roles of p16 INK4A and p53 in the growth arrest induced by E2FBP1 depletion, we examined seven human tumor cell lines (KB, A431, Hep-2, Saos2, two HCT116 derivatives and MCF7) by colony forming assay. Cells were transfected with either anti-E2FBP1 shRNA or control shRNA expressing plasmid and selected by puromycin. Colonies were detected by staining with crystal violet (Figure 5A and B) . E2FBP1 depletion clearly reduced the colony formation of KB and A431 cells that retain intact p16 INK4A and Rb. In contrast, other cell lines defective in either p16 INK4A and/or Rb showed no significant effect of E2FBP1-depletion on colony formation regardless of p53 status. These observations suggest that p16
INK4A -Rb pathway plays a critical role on growth arrest of tumor cells induced by E2FBP1 depletion, whereas the p53 status is insignificant. In the chart, vector control was set as 100% and error bars represent standard deviations of three independent assays.
